1. 
BACKGROUND INFORMATION ON THE PROCEDURE 
1.1. 
Submission of the dossier 
The  applicant  Neurim  Pharmaceuticals  EEC  Ltd.  submitted  on  5  October  2005  an  application  for 
Marketing  Authorisation  to  the  European  Medicines  Agency  (EMEA)  for  Circadin,  through  the 
centralised procedure under Article 3 (2) (a) of Regulation (EC) No 726/2004. The eligibility to the 
centralised procedure was agreed upon by the EMEA/CHMP on 24 June 2005.  
The legal basis for this application refers to:  
Article 8.3 of Directive 2001/83/EC, as amended - complete and independent application 
Scientific Advice: 
The applicant received Scientific Advice from the CHMP on 25 July 2002. The Scientific Advice 
pertained to clinical aspects of the dossier.  
Licensing status: 
The product was not licensed in any country at the time of submission of the application. 
The Rapporteur and Co-Rapporteur appointed by the CHMP and the evaluation teams were: 
Rapporteur: 
Co-Rapporteur: Dr. G. Aislaitner 
Prof. C. Sampaio 
1.2. 
Steps taken for the assessment of the product 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
The application was received by the EMEA on 5 October 2005.  
The procedure started on 26 October 2005. 
The  Rapporteur's  first  Assessment  Report  was  circulated  to  all  CHMP  members  on  10 
January  2006.  The  Co-Rapporteur's  first  Assessment  Report  was  circulated  to  all  CHMP 
members on 28 December 2005.  
During the meeting on 20-23 February 2006, the CHMP agreed on the consolidated List of 
Questions to be sent to the applicant. The final consolidated List of Questions was sent to the 
applicant on  24 February 2006. 
The  applicant  submitted  the  responses  to  the  CHMP  consolidated  List  of  Questions  on  29 
September 2006. 
The Rapporteurs circulated the Joint Assessment Report on the applicant’s responses to the 
List of Questions to all CHMP members on  27 October 2006. 
During  the  CHMP  meeting  on  13-16  November  2006,  the  CHMP  agreed  on  a  list  of 
outstanding issues to be addressed in writing and by the applicant. 
The Rapporteurs’ circulated the Joint Assessment Report on the applicant’s responses to the 
list of outstanding issues to all CHMP members on 8 March 2007. 
During the CHMP meeting on 19-22 March 2007, outstanding issues were addressed by the 
applicant during an oral explanation before the CHMP. 
During  the  meeting  on  23-26  April  2007,  the  CHMP,  in  the  light  of  the  overall  data 
submitted and the scientific discussion within the Committee, issued a positive opinion for 
granting a Marketing Authorisation to Circadin on 26 April 2007. The applicant provided the 
letter of undertaking on the follow-up measures to be fulfilled post-authorisation on 25 April 
2007. 
©EMEA 2007 
1/1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
